Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 19;7(3):ofaa054.
doi: 10.1093/ofid/ofaa054. eCollection 2020 Mar.

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

Michelle L Brown  1 , Johann Motsch  2 , Keith S Kaye  3 , Thomas M File  4 , Helen W Boucher  5 , Neika Vendetti  1 , Angela Aggrey  1 , Hee-Koung Joeng  1 , Robert W Tipping  1 , Jiejun Du  1 , Daryl D DePestel  1 , Joan R Butterton  1 , Amanda Paschke  1
Affiliations

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

Michelle L Brown et al. Open Forum Infect Dis. .

Abstract

Background: In the randomized controlled RESTORE-IMI 1 clinical trial (NCT02452047), imipenem/cilastatin (IMI) with relebactam (IMI/REL) was as effective as colistin plus IMI for the treatment of imipenem-nonsusceptible gram-negative infections. Differences in nephrotoxicity were observed between treatment arms. As there is no standard definition of nephrotoxicity used in clinical trials, we conducted analyses to further understand the renal safety profile of both treatments.

Methods: Nephrotoxicity was retrospectively evaluated using 2 acute kidney injury assessment criteria (Kidney Disease Improving Global Outcomes [KDIGO] and Risk, Injury, Failure, Loss, and End-stage Kidney Disease [RIFLE]). Additional outcomes included time to onset of protocol-defined nephrotoxicity and incidence of renal adverse events.

Results: Of 47 participants receiving treatment, 45 had sufficient data to assess nephrotoxicity (IMI/REL, n = 29; colistin plus IMI, n = 16). By KDIGO criteria, no participants in the IMI/REL but 31.3% in the colistin plus IMI group experienced stage 3 acute kidney injury. No IMI/REL-treated participants experienced renal failure by RIFLE criteria, vs 25.0% for colistin plus IMI. Overall, the time to onset of nephrotoxicity varied considerably (2-22 days). Fewer renal adverse events (12.9% vs 37.5%), including discontinuations due to drug-related renal adverse events (0% vs 12.5%), were observed in the IMI/REL group compared with the colistin plus IMI group, respectively.

Conclusions: Our analyses confirm the findings of a preplanned end point and provide further evidence that IMI/REL had a more favorable renal safety profile than colistin-based therapy in patients with serious, imipenem-nonsusceptible gram-negative bacterial infections.

Clinicaltrialsgov identifier: NCT02452047.

Keywords: IMI/REL; KDIGO criteria; RIFLE criteria; acute kidney injury; colistin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participants with protocol-defined nephrotoxicity or AKI by KDIGO or RIFLE criteria. If the patient met criteria for >1 AKI stage, they were only included once, in the worst-case stage. aTwo participants in the IMI/REL group with missing creatinine values were excluded from the nephrotoxicity and AKI evaluations.Abbreviations: AKI, acute kidney injury; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; KDIGO, Kidney Disease: Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss, and End-stage Kidney Disease.
Figure 2.
Figure 2.
Time to nephrotoxicity event. Abbreviations: cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; HABP, hospital-acquired bacterial pneumonia; IMI, imipenem/cilastatin; IMI/REL, imipenem/cilastatin plus relebactam; VABP, ventilator-associated bacterial pneumonia.
See this image and copyright information in PMC

References

    1. Cai B, Echols R, Magee G, et al. . Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis 2017; 4(X):XXX–XX. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf Accessed 17 August 2018.
    1. Judd WR, Ratliff PD, Hickson RP, et al. . Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. Am J Infect Control 2016; 44:1275–9. - PubMed
    1. Martin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis 2018; 5(X):XXX–XX. - PMC - PubMed
    1. Zilberberg MD, Nathanson BH, Sulham K, et al. . Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis 2017; 17:279. - PMC - PubMed

Associated data